Purification and Partial Biochemical Characterization of a Mycoplasma Fermentans-derived Substance That Activates Macrophages to Release Nitric Oxide, Tumor Necrosis Factor, and Interleukin-6
Overview
Authors
Affiliations
Mycoplasmal products may exert a number of diverse in vitro effects on cells of the immune system. A macrophage-activating substance from Mycoplasma fermentans was described in this laboratory and named mycoplasma-derived high-molecular-weight material (MDHM). Using synthesis of nitric oxide by peritoneal cells from endotoxin low-responder mice as an assay system, MDHM was purified as follows. After freeze-thawing of M. fermentans, MDHM activity was sedimented with the membrane fraction. Membranes were delipidated with chloroform-methanol, and MDHM activity was extracted with octyl glucoside. Coextracted proteins were degraded by proteinase K. MDHM was further purified by reversed-phase high-pressure liquid chromatography and eluted in one major and one minor peak of activity. Neither carbohydrates nor amino acids were found as constituents. MDHM had the following properties: it partitioned into the phenol phase upon phenol-water extraction and into the Triton phase after extraction with Triton X-114. MDHM was not inactivated by either phospholipase A2 or triglyceride lipases. However, mild periodate treatment led to a > 95% loss of activity. Also, alkaline hydrolysis at 25 degrees C completely abolished MDHM activity with a half-life of 2 min. MDHM activity was spread out over a wide molecular weight range upon sodium dodecyl sulfate-polyacrylamide gel electrophoresis of membranes, whereas after proteinase treatment MDHM activity migrated close to the front. These features of MDHM, taken together, speak in favor of an amphiphilic molecule with a lipid moiety carrying fatty acids in ester linkage and a polyol moiety of unknown character. MDHM was active in the nanogram-per-milliliter range, activating macrophages to release nitric oxide, interleukin-6, and tumor necrosis factor.
Liao D, Su X, Wang J, Yu J, Luo H, Tian W Front Immunol. 2023; 14:1113715.
PMID: 36761746 PMC: 9902699. DOI: 10.3389/fimmu.2023.1113715.
Santos Junior M, Neres N, Campos G, Bastos B, Timenetsky J, Marques L Front Vet Sci. 2021; 8:572171.
PMID: 33681318 PMC: 7930009. DOI: 10.3389/fvets.2021.572171.
The Role of Lipoproteins in Mycoplasma-Mediated Immunomodulation.
Christodoulides A, Gupta N, Yacoubian V, Maithel N, Parker J, Kelesidis T Front Microbiol. 2018; 9:1682.
PMID: 30108558 PMC: 6080569. DOI: 10.3389/fmicb.2018.01682.
Speda J, Johansson M, Odnell A, Karlsson M Biotechnol Biofuels. 2017; 10:129.
PMID: 28523077 PMC: 5434626. DOI: 10.1186/s13068-017-0814-0.
Cacciotto C, Addis M, Coradduzza E, Carcangiu L, Nuvoli A, Tore G PLoS One. 2013; 8(2):e57775.
PMID: 23469065 PMC: 3585158. DOI: 10.1371/journal.pone.0057775.